J&J earnings rise on strong consumer, pharma sales
Johnson & Johnson said its overall earnings increased 9.5% fueled by strong sales from its consumer products division and rising pharmaceutical sales.
J&J pharmaceutical sales were up 7.5% fueled by antipsychotic medication Risperdal, the drugmaker said Tuesday. Meanwhile J&J's consumer-product division saw sales rise 49% backed by a strong performance from Listerine antiseptic mouthwash, the launch of teeth-whitening products and Splenda sweetener among other products.
Johnson & Johnson announced it would purchase Pfizer's consumer healthcare business for $16.6 billion in June 2006, adding brands such as Listerine, Lubriderm, Visine, Neosporin, Sudafed, Zantac and Benadryl to its already lucrative consumer division.
“Consumer is the driving force for J&J, and will be through at least this year,'' said Bruce Cranna, an analyst with Leerink Swann & Co. in an interview with Bloomberg.com.
Johnson & Johnson sales data
(Sales to customers by segment of business)
US $15,603 $15,092
International $9,263 $8,175
US $6,408 $4,573
International $8,085 $5,201
-data provided by Johnson & Johnson